Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ATY001
MIFTS: 41

Atypical Depressive Disorder

Categories: Mental diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Atypical Depressive Disorder

About this section

MalaCards integrated aliases for Atypical Depressive Disorder:

Name: Atypical Depressive Disorder 12 15 72
Atypical Depression 12

Classifications:

MalaCards categories:
Anatomical: Mental diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:12294
ICD9CM 35 296.82
ICD10 33 F32.89
UMLS 72 C0154437
Sources

Summaries for Atypical Depressive Disorder

About this section
Disease Ontology : 12 A mood disorder that is characterized by mood reactivity (paradoxical anhedonia) and positivity, significant weight gain or increased appetite ("comfort eating"), excessive sleep or somnolence (hypersomnia), a sensation of heaviness in limbs known as leaden paralysis, and significant social impairment as a consequence of hypersensitivity to perceived interpersonal rejection.

MalaCards based summary : Atypical Depressive Disorder, also known as atypical depression, is related to avoidant personality disorder and social phobia. An important gene associated with Atypical Depressive Disorder is MAOA (Monoamine Oxidase A), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and Arginine and proline metabolism. The drugs Dopamine and Norepinephrine have been mentioned in the context of this disorder. Affiliated tissues include testes, pituitary and brain, and related phenotype is behavior/neurological.

Wikipedia : 75 Atypical depression as it has been known in the DSM IV, is depression that shares many of the typical... more...

Sources

Related Diseases for Atypical Depressive Disorder

About this section

Diseases related to Atypical Depressive Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 94)
# Related Disease Score Top Affiliating Genes
1 avoidant personality disorder 30.5 SLC6A4 MAOA
2 social phobia 30.4 SLC6A4 MAOA
3 agoraphobia 30.3 SLC6A4 MAOA
4 pure autonomic failure 29.8 MAOB MAOA
5 personality disorder 29.6 SLC6A4 MAOA HTR2A
6 dysthymic disorder 29.5 SLC6A4 MAOA HTR2A
7 drug dependence 29.4 SLC6A4 CRH
8 major depressive disorder 29.3 SLC6A4 MAOA HTR2A CRH
9 borderline personality disorder 29.2 SLC6A4 MAOA HTR2A
10 fibromyalgia 29.0 SLC6A4 HTR2A CRH
11 bulimia nervosa 29.0 SLC6A4 HTR2A
12 migraine with or without aura 1 28.9 SLC6A4 MAOA HTR2A
13 panic disorder 28.9 SLC6A4 MAOA HTR2A CRH
14 anxiety 28.8 SLC6A4 MAOA HTR2A CRH
15 endogenous depression 28.8 SLC6A4 MAOA HTR2A CRH
16 chronic fatigue syndrome 28.6 SLC6A4 MAOA HTR2A CRH
17 alcohol dependence 28.4 SLC6A4 MAOB MAOA HTR2A
18 mental depression 28.4 SLC6A4 MAOA HTR2A CRH
19 depression 28.4 SLC6A4 MAOA HTR2A CRH
20 disease of mental health 28.2 SLC6A4 MAOA HTR2A CRH
21 obsessive-compulsive disorder 28.2 SLC6A4 MAOA HTR2A CRH
22 mood disorder 28.1 SLC6A4 MAOB MAOA HTR2A CRH
23 hypersomnia 10.4
24 exhibitionism 10.3 MAOB MAOA
25 dependent personality disorder 10.3 MAOB MAOA
26 dystonia 1, torsion, autosomal dominant 10.3 MAOB MAOA
27 melancholia 10.2
28 paraphilia disorder 10.2 MAOB MAOA
29 phobic disorder 10.2 SLC6A4 MAOA
30 kleptomania 10.2 SLC6A4 MAOA
31 oppositional defiant disorder 10.2 SLC6A4 MAOA
32 hepatic encephalopathy 10.2 MAOB MAOA
33 norrie disease 10.1 MAOB MAOA
34 major affective disorder 8 10.1
35 major affective disorder 9 10.1
36 bipolar disorder 10.1
37 adrenal cortex disease 10.1 NR3C2 CRH
38 adrenal gland disease 10.1 NR3C2 CRH
39 conduct disorder 10.1 SLC6A4 MAOA
40 irritable bowel syndrome 10.0 SLC6A4 CRH
41 substance abuse 10.0 SLC6A4 MAOA
42 chronic pain 9.9
43 eating disorder 9.9 SLC6A4 CRH
44 postpartum depression 9.9 SLC6A4 MAOA CRH
45 brunner syndrome 9.9 SLC6A4 MAOB MAOA
46 antisocial personality disorder 9.9 SLC6A4 MAOB MAOA
47 severe combined immunodeficiency 9.9
48 psychosexual disorder 9.8 SLC6A4 HTR2A
49 alcoholic psychosis 9.8 SLC6A4 HTR2A
50 periodic limb movement disorder 9.8 SLC6A4 HTR2A

Comorbidity relations with Atypical Depressive Disorder via Phenotypic Disease Network (PDN):


Acute Cystitis Anxiety
Deficiency Anemia Dysthymic Disorder
Hypertension, Essential Hypothyroidism
Major Depressive Disorder Parkinson Disease, Late-Onset
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Atypical Depressive Disorder:



Diseases related to Atypical Depressive Disorder
Sources

Symptoms & Phenotypes for Atypical Depressive Disorder

About this section

MGI Mouse Phenotypes related to Atypical Depressive Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.1 CRH HTR2A MAOA MAOB NR3C2 SLC6A4
Sources

Drugs & Therapeutics for Atypical Depressive Disorder

About this section

DrugBank drugs 16 :

# Drug Name Indication DrugBank ID
1 Phenelzine Phenelzine is indicated for the treatment of nonendogenous, neurotic or atypical depression for patients that do not tolerate other forms of therapy.[L1356] Atypical depression has a high prevalence rate, starts in early life, tends to last longer, is more likely to occur in people with bipolar disorder, has a high comorbidity with anxiety disorder and carries more risk of suicidal behavior. It is important to specify the atypical feature to predict the clinical course of depression and hence generate the best treatment and service. The featuring symptoms of the atypical feature include mood reactivity, two or more of this symptoms: 1) increased appetite, 2) increased sleep, 3) leaden paralysis and 4) interpersonal rejection sensitivity and should not have melancholic or catatonic features of depression.[A31917] Neurotic depression is a depression of an emotionally unstable person. It is a secondary condition to major personality disorder, neuroses and drug use disorders. Likewise, a primary depression with a family history of depression spectrum disease would fit in this category.[A31922] A nonendogenous depression is characterized by a disturbance in mood and general outlook. The physical symptoms tend to be less severe and it often occurs in response to stressful life events that keep occurring over a large period of time generating a continuous stress in the daily living.[A31924] DB00780

Drugs for Atypical Depressive Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 59)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
2
Norepinephrine Approved Phase 4 51-41-2 439260
3
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
4
Ziprasidone Approved Phase 4 146939-27-7 60854
5 Neurotransmitter Agents Phase 4
6 Analgesics Phase 4
7 Psychotropic Drugs Phase 4
8 Neurotransmitter Uptake Inhibitors Phase 4
9 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
10 Peripheral Nervous System Agents Phase 4
11 Duloxetine Hydrochloride Phase 4
12 Dopamine Agents Phase 4
13 Antidepressive Agents Phase 4
14 Antidepressive Agents, Second-Generation Phase 4
15 Serotonin Agents Phase 4
16 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
17 Cytochrome P-450 Enzyme Inhibitors Phase 4
18 Dopamine Uptake Inhibitors Phase 4
19 Tranquilizing Agents Phase 4
20 Central Nervous System Depressants Phase 4
21 Serotonin Antagonists Phase 4
22 Antipsychotic Agents Phase 4
23 Dopamine Antagonists Phase 4
24
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
25
Modafinil Approved, Investigational Phase 2, Phase 3 68693-11-8 4236
26
Citalopram Approved Phase 3 59729-33-8 2771
27
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
28 Cytochrome P-450 CYP3A Inducers Phase 2, Phase 3
29 Cytochrome P-450 Enzyme Inducers Phase 2, Phase 3
30 Central Nervous System Stimulants Phase 2, Phase 3
31 Wakefulness-Promoting Agents Phase 2, Phase 3
32 Parasympatholytics Phase 3
33 Serotonin Uptake Inhibitors Phase 3
34 Cholinergic Agents Phase 3
35 Muscarinic Antagonists Phase 3
36 Cholinergic Antagonists Phase 3
37 Antiparkinson Agents Phase 3
38 Autonomic Agents Phase 3
39
Chromium Approved Phase 1, Phase 2 7440-47-3 27668
40
Iron Approved, Experimental Phase 1, Phase 2 15438-31-0, 7439-89-6 23925 27284
41
Histamine Approved, Investigational Phase 2 51-45-6 774
42
Betahistine Approved, Investigational Phase 2 5638-76-6 2366
43 Chelating Agents Phase 1, Phase 2
44
Picolinic acid Phase 1, Phase 2 98-98-6 1018
45 Micronutrients Phase 1, Phase 2
46 Iron Chelating Agents Phase 1, Phase 2
47 Nutrients Phase 1, Phase 2
48 Trace Elements Phase 1, Phase 2
49
Histamine Phosphate Phase 2 51-74-1 65513
50 Vasodilator Agents Phase 2

Interventional clinical trials:

(show all 14)
# Name Status NCT ID Phase Drugs
1 A Pilot Study Assessing Duloxetine's Efficacy in Atypical Depression Completed NCT00296699 Phase 4 Duloxetine
2 An Open-Label, 8-week Trial of Bupropion Hydrochloride Extended Release (Wellbutrin XL®) In Patients With Major Depressive Disorder (MDD) With Atypical Features. Completed NCT01477931 Phase 4 Bupropion extended release
3 Duloxetine for Chronic Depression: a Double-blind Study Completed NCT00360724 Phase 4 Duloxetine (Cymbalta)
4 Predictors of Response to Augmentation With Ziprasidone (Geodon®) in Major Depressive Disorder : A 13-week, Double-Blind, Placebo-Controlled, Cross-Over Trial Completed NCT01168674 Phase 4 ziprasidone;Sugar pill
5 A Study of Modafinil for Atypical Depression Completed NCT00215176 Phase 2, Phase 3 modafinil
6 St. John's Wort Extract LI 160 for the Treatment of Atypical Depression Completed NCT00861978 Phase 3 St. John's Wort extract;Placebo
7 A Pilot Study -- An Open-Label, Rater-blinded, Flexible-dose, 8-week Trial of Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features. Completed NCT00610506 Phase 3 Escitalopram
8 Efficacy of Light Therapy for Bipolar Depression: A Randomized Controlled Trial Completed NCT00852592 Phase 3
9 Chromium Picolinate in Binge Eating Disorder: A Feasibility Study Completed NCT00904306 Phase 1, Phase 2
10 A Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features Terminated NCT00585585 Phase 2 betahistine dihydrochloride
11 Atomoxetine, Diurnal Profiles of Cortisol and α-amylase, Possible Biological Markers of Treatment Success Unknown status NCT03075579 Medication Other
12 The Effect of Gastric Bypass on the Pharmacokinetics of Serotonin Reuptake Inhibitors Completed NCT01317147
13 A Multicenter, Randomized, Blinded, Controlled, Parallel Group Trial to Demonstrate the Efficacy of rEEG Guided Pharmacotherapy of Subjects With Depression Treatment Failure Completed NCT00437827
14 Postnatal Depression, Attachment and Self-defining Memories Recruiting NCT03346551

Search NIH Clinical Center for Atypical Depressive Disorder

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Phenelzine
Sources

Genetic Tests for Atypical Depressive Disorder

About this section
Sources

Anatomical Context for Atypical Depressive Disorder

About this section

MalaCards organs/tissues related to Atypical Depressive Disorder:

41
Testes, Pituitary, Brain, Thyroid, Spinal Cord, Cortex, Adipocyte
Sources

Publications for Atypical Depressive Disorder

About this section

Articles related to Atypical Depressive Disorder:

(show top 50) (show all 573)
# Title Authors PMID Year
1
Circulating leptin, cortisol and gender differences associated with anorexia or obesity in depression. 38
31347937 2019
2
Genetic variation of the mineralocorticoid receptor gene (MR, NR3C2) is associated with a conceptual endophenotype of "CRF-hypoactivity". 38
30292651 2019
3
Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells. 38
30693539 2019
4
Characteristics, comorbidities, and correlates of atypical depression: evidence from the UK Biobank Mental Health Survey. 38
31044683 2019
5
Association between mood disorders and BMI/overweight using a family study approach. 38
30731280 2019
6
Clinical Predictors of Response to Magnetic Seizure Therapy in Depression: A Preliminary Report. 38
29613946 2019
7
Prevalence and clinical features of atypical depression among patients with major depressive disorder in China. 38
30594041 2019
8
Sultans of Swing: A Reappraisal of the Intertwined Association Between Affective Lability and Mood Reactivity in a Post Hoc Analysis of the BRIDGE-II-MIX Study. 38
30786180 2019
9
Selegiline ameliorates depression-like behaviors in rodents and modulates hippocampal dopaminergic transmission and synaptic plasticity. 38
30359642 2019
10
The association of serum C-reactive protein with the occurrence and course of postpartum depression. 38
29654412 2019
11
Prevalence and risk factors of excessive daytime sleepiness in major depression: A study with 703 individuals referred for polysomnography. 38
30223136 2019
12
Chronic Atypical Depression as an Early Feature of Pituitary Adenoma: A Case Report and Literature Review. 38
31428501 2019
13
Bipolar features in major depressive disorder: Results from the Iranian mental health survey (IranMHS). 38
30142591 2018
14
Mapping depression rating scale phenotypes onto research domain criteria (RDoC) to inform biological research in mood disorders. 38
29807322 2018
15
Opposite Molecular Signatures of Depression in Men and Women. 38
29548746 2018
16
Prevalence of seasonal depression in a prospective cohort study. 38
30022319 2018
17
Atypical depression and non-atypical depression: Is HPA axis function a biomarker? A systematic review. 38
29150144 2018
18
Antiepileptic effect of olanzapine in epilepsy patients with atypical depressive comorbidity. 38
29905158 2018
19
Metabolic and inflammatory markers: associations with individual depressive symptoms. 38
28889804 2018
20
Short-term and long-term measures of cortisol in saliva and hair in atypical and non-atypical depression. 38
29397570 2018
21
Are there differences in lipid peroxidation and immune biomarkers between major depression and bipolar disorder: Effects of melancholia, atypical depression, severity of illness, episode number, suicidal ideation and prior suicide attempts. 38
28867391 2018
22
Adjunctive Bright Light Therapy for Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Trial. 38
28969438 2018
23
Atypical depression and double depression predict new-onset cardiovascular disease in U.S. adults. 38
28640965 2018
24
[Clinical-psychopathological aspects of therapeutic effects of agomelatine (valdoxan) and its place in perfection of methods of therapy of postschizophrenic depressive disorders]. 38
29652308 2018
25
[The features of psychopharmacotherapy of depressive states with panic attacks]. 38
29863695 2018
26
Big Five personality characteristics are associated with depression subtypes and symptom dimensions of depression in older adults. 38
28092410 2017
27
The relationship between atypical depression and insülin resistance in patients with polycystic ovary syndrome and major depression. 38
28168992 2017
28
Schizophrenia dissection by five anxiety and depressive subtype comorbidities: Clinical implications and evolutionary perspective. 38
28763736 2017
29
Telephone-Based Depression Care Management for Postpartum Women: A Randomized Controlled Trial. 38
28796940 2017
30
Associations of Serum Cytokine Receptor Levels with Melancholia, Staging of Illness, Depressive and Manic Phases, and Severity of Depression in Bipolar Disorder. 38
27660275 2017
31
A combined marker of early non-improvement and the occurrence of melancholic features improve the treatment prediction in patients with Major Depressive Disorders. 38
28647668 2017
32
Depression differed by midnight cortisol secretion, alexithymia and anxiety between diabetes types: a cross sectional comparison. 38
28931368 2017
33
Is atypical depression simply a typical depression with unusual symptoms? 38
28754056 2017
34
Tranylcypromine in mind (Part II): Review of clinical pharmacology and meta-analysis of controlled studies in depression. 38
28579071 2017
35
Bipolar At-Risk Criteria: An Examination of Which Clinical Features Have Optimal Utility for Identifying Youth at Risk of Early Transition From Depression to Bipolar Disorders. 38
27872258 2017
36
Mood symptoms in pregnant and postpartum women with bipolar disorder: a naturalistic study. 38
28665044 2017
37
Leptin Dysregulation Is Specifically Associated With Major Depression With Atypical Features: Evidence for a Mechanism Connecting Obesity and Depression. 38
26742925 2017
38
Melancholic and atypical depression as predictor and moderator of outcome in cognitive behavior therapy and pharmacotherapy for adult depression. 38
27921338 2017
39
Musculoskeletal Pain in Melancholic and Atypical Depression. 38
28204727 2017
40
Neuropsychological changes in melancholic and atypical depression: A systematic review. 38
28027956 2017
41
[Development of the Interpersonal Sensitivity/Privileged Self Scale: The measurement of a psychological characteristic related to “Modern-type Depression”]. 38
29630299 2017
42
Why do stimulants not work in typical depression? 38
27807011 2017
43
Atypical depression: current perspectives. 38
29033570 2017
44
Efficacy of curcumin, and a saffron/curcumin combination for the treatment of major depression: A randomised, double-blind, placebo-controlled study. 38
27723543 2017
45
Bipolar disorder and antithyroid antibodies: review and case series. 38
26869176 2016
46
Antidepressant treatment differentially affects the phenotype of high and low stress reactive mice. 38
27395785 2016
47
Familial aggregation and heritability of the melancholic and atypical subtypes of depression. 38
27450632 2016
48
Factors associated with onset timing, symptoms, and severity of depression identified in the postpartum period. 38
27285724 2016
49
Adult with Middle Interhemispheric Variant of Holoprosencephaly: Neuropsychological, Clinical, and Radiological Findings. 38
27235161 2016
50
Atypical depressive symptoms as a predictor of treatment response to exercise in Major Depressive Disorder. 38
27136412 2016
Sources

Variations for Atypical Depressive Disorder

About this section
Sources

Expression for Atypical Depressive Disorder

About this section
Search GEO for disease gene expression data for Atypical Depressive Disorder.
Sources

Pathways for Atypical Depressive Disorder

About this section

Pathways related to Atypical Depressive Disorder according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
11.75 SLC6A4 MAOA HTR2A
2
Arginine and proline metabolism 37
Show member pathways
 11.25 MAOB MAOA
3
Glycine, serine and threonine metabolism 37
Show member pathways
 11.19 MAOB MAOA
4
Monoamine Transport 1
Show member pathways
 11.09 SLC6A4 MAOA
5
Serotonergic synapse 37
10.98 SLC6A4 MAOB MAOA HTR2A
6
Histidine metabolism 37
Show member pathways
 10.96 MAOB MAOA
7
Neurotransmitter Clearance In The Synaptic Cleft 66
Show member pathways
 10.82 SLC6A4 MAOA
8
Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics 61
10.58 SLC6A4 MAOA HTR2A
9
noradrenaline and adrenaline degradation 1
Show member pathways
 10.5 MAOB MAOA
10
Dopamine metabolism 1
10.4 MAOB MAOA
11
putrescine degradation III 1
Show member pathways
 10.27 MAOB MAOA
Sources

GO Terms for Atypical Depressive Disorder

About this section

Cellular components related to Atypical Depressive Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of presynaptic membrane GO:0099056 8.96 SLC6A4 HTR2A
2 integral component of postsynaptic membrane GO:0099055 8.62 SLC6A4 HTR2A

Biological processes related to Atypical Depressive Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to toxic substance GO:0009636 9.37 SLC6A4 MAOB
2 memory GO:0007613 9.32 SLC6A4 HTR2A
3 response to corticosterone GO:0051412 9.26 MAOB CRH
4 neurotransmitter catabolic process GO:0042135 9.16 MAOB MAOA
5 dopamine catabolic process GO:0042420 8.96 MAOB MAOA
6 response to drug GO:0042493 8.92 SLC6A4 MAOB HTR2A CRH

Molecular functions related to Atypical Depressive Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serotonin binding GO:0051378 8.96 SLC6A4 HTR2A
2 primary amine oxidase activity GO:0008131 8.62 MAOB MAOA
Sources

Sources for Atypical Depressive Disorder

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....